Riwaroksaban – nowe możliwości leczenia przeciwkrzepliwego w migotaniu przedsionków Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2011
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Szulik, M., & Kalarus, Z. (2011). Riwaroksaban – nowe możliwości leczenia przeciwkrzepliwego w migotaniu przedsionków . Medycyna Faktów , 4(4(13), 23-25. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2501
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Kubitza D., Becka M., Wensing G., Voith B., Zuehlsdorf M.: Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 2005; 61: 873-880.
2. Durham N.C., The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators: Rivaroxaban – Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study. Am. Heart J. 2010; 159: 340-347.
3. Wittkowsky A.K.: Effective Anticoagulation Therapy: Defining the Gap Between Clinical Studies and Clinical Practice. Am. J. Manag. Care 2004; 10: 297-306.
4. Supplementary Appendix. Patel M.R., Mahaffey K.W., Garg J. et al.: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011 [DOI: 0.1056/NEJMoa1009638].
5. Patel M., Kenneth W. et al., The ROCKET AF Steering Committee, for the ROCKET AF Investigators: Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N. Engl. J. Med. 2011; 365: 883-891.
6. Mega J.L., Braunwald E., Wiviott S.D. et al.: The ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N. Engl. J. Med. 2011 [DOI: 10.1056/NEJMoa1112277].
7. Granger C.B., Alexander J.H., McMurray J.J. et al., ARISTOTLE Committees and Investigators: Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011; 15(365): 981-992.
8. Ruff C.T., Giugliano R.P., Antman E.M. et al.: Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J. 2010; 160: 635-641.
9. Iwatsuki Y., Sato T., Moritani Y. et al.: Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur. J. Pharmacol. 2011; 673: 49-55.
2. Durham N.C., The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators: Rivaroxaban – Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study. Am. Heart J. 2010; 159: 340-347.
3. Wittkowsky A.K.: Effective Anticoagulation Therapy: Defining the Gap Between Clinical Studies and Clinical Practice. Am. J. Manag. Care 2004; 10: 297-306.
4. Supplementary Appendix. Patel M.R., Mahaffey K.W., Garg J. et al.: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011 [DOI: 0.1056/NEJMoa1009638].
5. Patel M., Kenneth W. et al., The ROCKET AF Steering Committee, for the ROCKET AF Investigators: Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N. Engl. J. Med. 2011; 365: 883-891.
6. Mega J.L., Braunwald E., Wiviott S.D. et al.: The ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N. Engl. J. Med. 2011 [DOI: 10.1056/NEJMoa1112277].
7. Granger C.B., Alexander J.H., McMurray J.J. et al., ARISTOTLE Committees and Investigators: Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011; 15(365): 981-992.
8. Ruff C.T., Giugliano R.P., Antman E.M. et al.: Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J. 2010; 160: 635-641.
9. Iwatsuki Y., Sato T., Moritani Y. et al.: Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur. J. Pharmacol. 2011; 673: 49-55.